Plus Therapeutics shares lost 50.1% on August 15, 2025, compared to the S&P 500's 10% gain.
2 reports, 2 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Plus Therapeutics shares lost 50.1% on August 15, 2025, compared to the S&P 500's 10% gain.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Plus Therapeutics
biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksPlus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates Plus Therapeutics (PSTV) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. T
- GlobeNewswirePlus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes